Please ensure Javascript is enabled for purposes of website accessibility
Accueil > Products > Protéines Recombinantes > Protéines de Point de Contrôle Immunologique

Human VEGFR2/KDR/Flk-1 Recombinant Protein (C-His) (HW338011)

Human VEGFR2/KDR/Flk-1 Recombinant Protein (C-His)
Human VEGFR2/KDR/Flk-1 Recombinant Protein (C-His)
Human VEGFR2/KDR/Flk-1 Recombinant Protein (C-His)
Human VEGFR2/KDR/Flk-1 Recombinant Protein (C-His)
Human VEGFR2/KDR/Flk-1 Recombinant Protein (C-His)
Human VEGFR2/KDR/Flk-1 Recombinant Protein (C-His)
Prix(USD) :
Spécification :
  • 50ug
  • 100ug
  • 1mg
Nombre :
Contactez-nous
  • Aperçu

  • Images

  • Reférences

  • Fiche technique

  • SDS

Aperçu
Numéro de catalogueHW338011
Description
Recombinant Human CD309/KDR/VEGFR-2 Protein, C-His (HW338011) expressed in Mammalian Cells, spanning Met1-Glu764. Purity: >90% by SDS-PAGE.
Highlights
  • ●His-Tagged — N-terminal 6×His tag for IMAC purification.
  • ●Mammalian Expression — Proper folding and native glycosylation.
  • ●High Purity — >90% purity verified by SDS-PAGE.
Système d'expressionMammalian cells
Numéro d'accèsP35968
Longueur de protéineMet1-Glu764
ApplicationsELISA, Immunogen, SDS-PAGE, WB, Bioactivity testing in progress
EspècesHomo sapiens (Human)
Nature Recombinant
Cible CD309, EC:2.7.10.1, FLK-1, FLK1, Fetal liver kinase 1, KDR, Kinase insert domain receptor, Protein-tyrosine kinase receptor flk-1, VEGFR-2, VEGFR2, Vascular endothelial growth factor receptor 2
Niveau d'endotoxines Please contact with the lab for this information.
Pureté >90% as determined by SDS-PAGE.
Masse moléculaire prédite 86.37 kDa
Forme Lyophilized
Tampon de stockage Lyophilized from a solution in PBS pH 7.4, 1 mM EDTA, 4% Trehalose, 1% Mannitol.

Reférez-vous aux informations spécifiques sur le tampon dans la copie papier du datasheet ou dans le COA spécifique au lot.

Reconstitution Reconstitute in sterile water for a stock solution. Adjust the volume of sterile water so that, after reconstitution, the final stock concentration matches the value indicated on the product label or datasheet.

RECONSTITUTION PROTOCOL
1. Allow the product to be reconstituted and the reconstitution diluent to reach room temperature.
2. Tap or briefly centrifuge the product vial before opening to dislodge any lyophilized material that may be dispersed on the wall or cap of the vial.
3. Use the diluent and stock concentration recommended in the product datasheet. If preparing a stock concentration higher than recommended, contact Technical Service.
4. After adding the diluent, re-cap the vial and invert gently by hand or place on a slow rocking platform to allow the reconstitution diluent to coat all the surfaces inside the vial. Note: Do not mix by vortexing or by pipetting the material up and down.
5. Allow the vial to sit at room temperature with gentle agitation for at least 15 minutes before aliquotting or using.
6. Store the reconstituted material in single use aliquots in polypropylene or siliconized tubes. Aliquots of 10 μL or larger are recommended.
Expédition In general, proteins are provided as lyophilized powder/frozen liquid. They are shipped out with dry ice/blue ice unless customers require otherwise.
Stabilité et stockage Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Noms alternatifsCD309, EC:2.7.10.1, FLK-1, FLK1, Fetal liver kinase 1, KDR, Kinase insert domain receptor, Protein-tyrosine kinase receptor flk-1, VEGFR-2, VEGFR2, Vascular endothelial growth factor receptor 2
Contexte

Vascular endothelial growth factor receptor 2 (CD309/VEGFR-2) is a ~151 kDa protein. Tyrosine-protein kinase that acts as a cell-surface receptor for VEGFA, VEGFC and VEGFD. Plays an essential role in the regulation of angiogenesis, vascular development, vascular permeability, and embryonic hematopoiesis. Promotes proliferation, survival, migration and differentiation of endothelial cells. Promotes reorganization of the actin cytoskeleton. Isoforms lacking a transmembrane domain, such as isoform 2 and isoform 3, may function as decoy receptors for VEGFA, VEGFC and/or VEGFD. CD309 is the therapeutic target of ramucirumab (Cyramza).

Note For research use only.
Images
  • Human VEGFR2/KDR/Flk-1 Recombinant Protein (C-His)

    SDS-PAGE

    SDS-PAGE for Recombinant Human CD309/KDR/VEGFR-2 Protein, C-His

  • Human VEGFR2/KDR/Flk-1 Recombinant Protein (C-His)

    Bioactivity

    Detected by SAA1230 (Catalog No: HW338023) in indirect ELISA.

  • Human VEGFR2/KDR/Flk-1 Recombinant Protein (C-His)

    Bioactivity

    Detected by Pulocimab (Catalog No: HW338066) in indirect ELISA.

Reférences
Formula
Mass (g) = Concentration (mol/L) × Volume (L) × MW (g/mol)
Enter any 2 of Mass, Concentration, Volume + Molecular Weight to solve for the unknown.
Mass
=
Concentration
×
Volume
Molecular Weight *
g/mol
Formula
C₁ × V₁ = C₂ × V₂
Enter any 3 of the 4 values to solve for the unknown.
Stock Solution
C₁ (Stock Conc.)
×
V₁ (Stock Vol.)
=
Working Solution
C₂ (Working Conc.)
×
V₂ (Working Vol.)
Recommandation

Contactez-nous pour les devis personnalisés, les demandes en gros et tout autre problème.

Courrier : [email protected]

Liste des distributeurs